제목 포스트 코로나 시대 대중남미 협력 방안: 의료 및 방역 부문을 중심으로
분류 생명공학/바이오 판매자 조정희 조회수 61
용량 5.6MB 필요한 K-데이터 7도토리
파일 이름 용량 잔여일 잔여횟수 상태 다운로드
포스트 코로나 시대 대중남미 협력 방안 의료 및 방역 부문을 중심으로.pdf 5.6MB - - - 다운로드
데이터날짜 : 2021-06-21 
출처 : 정부산하기관 
페이지 수 : 420 

국문요약 ···································································································· 3
제1장 서론 ······························································································ 21
1. 연구 목적 ······························································································22
2. 연구의 주요 내용 ··················································································24
가. 중남미 지역의 의료ㆍ방역 환경 ·····················································24
나. 중남미 주요국의 코로나 방역역량과 의료 인프라 ·························25
다. 포스트 코로나 시대 중남미 방역ㆍ의료시장과 디지털 전환 ··········29
라. 한-중남미 의료ㆍ방역 협력 방향 ····················································34
마. 결론 ·································································································35
3. 연구방법 ································································································36
가. 코로나19 확산 요인 검토 ·······························································36
나. 진출단위로서의 HEPI 모델과 레고형 진출방안 ·····························37
4. 연구의 차별성과 기대효과 ····································································41
가. 선행연구와 차별성 ··········································································41
나. 기대효과 ··························································································45
제2장 중남미 지역의 의료ㆍ방역 환경 ······················································47
1. 사회ㆍ문화적 특성 ················································································48
가. 사회ㆍ인구학적 구성 ······································································48
나. 문화적 특성 ·····················································································53
2. 보건ㆍ의료체계 ·····················································································56
가. 아르헨티나 ······················································································59
나. 볼리비아 ··························································································61

다. 브라질 ·····························································································62
라. 콜롬비아 ··························································································64
마. 멕시코 ·····························································································67
바. 파라과이 ··························································································69
사. 페루 ·································································································70
아. 에콰도르 ··························································································72
3. 사회안전망 ····························································································73
제3장 중남미 주요국의 코로나 방역역량과 의료 인프라 ···························77
1. 브라질 ···································································································78
가. 코로나19 발생 동향 ········································································78
나. 정부의 코로나19 대응 정책 ···························································84
다. 경제적 역량과 보건ㆍ의료 지출 ·····················································91
라. 코로나 통제와 브라질 경제사회구조 ··············································96
마. 코로나 대응 의료역량과 자원 ·························································99
바. 디지털 헬스 역량 ··········································································108
2. 멕시코 ·································································································115
가. 코로나19 발생 동향 ······································································115
나. 정부의 코로나19 대응 정책 ··························································116
다. 경제적 역량과 보건ㆍ의료 지출 ···················································122
라. 코로나 통제와 멕시코 사회경제구조 ············································124
마. 코로나 대응 의료역량과 자원 ·······················································126
바. 디지털 헬스 역량 ··········································································136
3. 아르헨티나 ··························································································140
가. 코로나19 발생 동향 ······································································140

나. 정부의 코로나19 대응 정책 ··························································142
다. 경제적 역량과 보건ㆍ의료 지출 ···················································149
라. 코로나 통제와 아르헨티나 경제사회구조 ·····································152
마. 코로나 대응 의료역량과 자원 ·······················································155
바. 디지털 헬스 역량 ··········································································163
4. 페루 ·····································································································169
가. 코로나19 발생 동향 ······································································169
나. 정부의 코로나19 대응 정책 ··························································170
다. 경제적 역량과 보건ㆍ의료 지출 ···················································175
라. 코로나 통제와 페루의 경제사회구조 ············································179
마. 코로나19 대응 의료역량과 자원 ··················································183
바. 디지털 헬스 역량 ··········································································190
5. 에콰도르 ·····························································································196
가. 코로나19 발생 동향 ······································································196
나. 정부의 코로나19 대응 정책 ··························································198
다. 경제적 역량과 보건ㆍ의료 지출 ···················································203
라. 코로나 통제와 에콰도르의 사회경제구조 ·····································206
마. 코로나 대응 의료역량과 자원 ·······················································208
바. 디지털 헬스 역량 ··········································································215
제4장 포스트 코로나 시대 중남미 방역ㆍ의료 시장과 디지털 전환 ········223
1. 중남미 방역ㆍ의료 능력과 K-방역협력 모델 ·····································224
가. 병원과 의료진 ···············································································226
나. 의료장비 및 의료용품 ···································································228
다. 방역 프로그램 ···············································································232

라. K-방역 표준화와 중남미 진출 ······················································245
2. 포스트 코로나 시대 중남미 ICT 능력과 디지털 의료시장 ·················251
가. 포스트 코로나 시대의 변화 ··························································251
나. 중남미 ICT 인프라 ·······································································257
다. 중남미 보건ㆍ의료 ICT 진출 분야 ···············································269
제5장 한-중남미 의료ㆍ방역 협력 방향 ·················································293
1. 시장 부문 ····························································································295
가. 의료기기 시장진출 ········································································295
나. 인구통계학적 특성을 반영한 맞춤형 시장전략 ····························298
다. 새로운 수요층을 고려한 보험시장 진출 ·······································299
라. 국별 사업환경 분석을 바탕으로 한 시장진출 ·······························300
마. 디지털 보건ㆍ의료 사업 진출 ·······················································302
2. 국제개발협력 부문 ··············································································305
가. 개발원조의 활용 ···········································································305
나. 취약집단 중심 협력 지원 ······························································308
3. 제도 및 정책추진 부문 ········································································311
가. 기술개발 파트너십 구축 ·······························································311
나. 정책 경험 공유 ··············································································311
다. 의료지원 인력 수급 원활화 협력 ··················································312
라. 의료ㆍ방역 협력 제도화 ·······························································314
마. 지역기구와의 파트너십 형성 ························································316
제6장 결론: 대중남미 보건ㆍ의료 진출전략 ············································319
1. 코로나19가 한-중남미 협력에 주는 시사점 ·······································320

2. 국가별 보건ㆍ의료 부문 분석과 진출전략 ··········································324
가. 브라질 ···························································································324
나. 멕시코 ···························································································330
다. 아르헨티나 ····················································································336
라. 페루 ·······························································································343
마. 에콰도르 ·······················································································348
3. 종합: 중남미 방역ㆍ의료 부문의 도전과 한국의 진출전략 ················352
참고문헌 ··································································································360
Executive Summary ············································································408

 

 

전 세계 대부분 국가가 코로나19 통제를 위해 봉쇄와 이동 제한, 통금 등의 조치를 발동하였으나, 한국은 이러한 조치 없이 코로나19의 조기 확산 방지에 성공하였다. 세계 주요 언론은 한국정부의 코로나19 확산 방지 및 통제 성공 사례를 헤드라인으로 소개하여 방역 선진국으로서 한국의 면모를 전 세계에 깊이 각인시켰다. 이러한 한국의 방역 역량은 질병 관리 당국의 신속한 대응과 감염자 및 접촉자 추적을 위한 정보통신기술(ICT)의 활용에 의거한 것이다. K-방역으로 불리는 한국의 성공적 방역 모델은 3T(Test-Trace-Treatment)를 핵심요소로 하고 있으며 한국은 K-방역 모델을 전 세계에 전파하여 인류 건강 증진에 기여하려 하고 있다. 본 연구는 중남미 국가의 확산 방지 실패 요인을 분석하여 코로나 같은 감염병의 재발을 막기 위해 한국의 방역 역량을 어떻게 활용할 수 있는가를 염두에 두고 이를 통해 한국과 중남미 국가 간의 방역 및 의료 협력의 기본 방향을 제시하려 한다.

 



※ 본 서비스에서 제공되는 각 저작물의 저작권은 자료제공사에 있으며 각 저작물의 견해와 DATA 365와는 견해가 다를 수 있습니다.

List of Articles
번호 분류 제목 K-데이터 판매자
K데이터 무통장 입금을 통한 충전 방법
1189 성장동력산업 2021년 3분기 해외직접투자 동향분석 1도토리 국준아
1188 성장동력산업 해외 ICT 표준화 동향 (2021년 6월-3) 1도토리 조정희
1187 성장동력산업 독일 폐수 분야의 기후 및 에너지 효율 분석 보고서 1도토리 조정희
1186 성장동력산업 미국 탄소 포집 기술 연구 동향 및 향후 전망 1도토리 조정희
1185 성장동력산업 2022년 국내 및 국외 경제·산업 전망 3도토리 국준아
1184 성장동력산업 고전압, 대전류의 고정형 아노드 디지털 엑스선 튜브 기술 1도토리 조정희
1183 성장동력산업 해양 환경 규제를 통한 신규 조선 발주 전망 3도토리 국준아
1182 성장동력산업 EU 의회 기업실사지침안의 주요 내용과 시사점 1도토리 조정희
1181 성장동력산업 포스트 COVID-19 시대 아프리카 ICT 국제개발 협력수요와 韓의 협력방안 7도토리 조정희
» 생명공학/바이오 포스트 코로나 시대 대중남미 협력 방안: 의료 및 방역 부문을 중심으로 7도토리 조정희
1179 성장동력산업 석유가스 시장 분기동향 보고서(2021년 2분기) 1도토리 국준아
1178 성장동력산업 동아프리카 스타트업 시장분석과 韓 기업의 진출방안 7도토리 조정희
1177 성장동력산업 코로나19 이후 글로벌 200대 은행 실적 변화 1도토리 조정희
1176 성장동력산업 메타버스 금융서비스 개발 본격화 1도토리 조정희
1175 성장동력산업 디지털 시대, 개인정보 보호의 중요성 증가 1도토리 조정희
1174 성장동력산업 외환: 테이퍼링 우려 부각되며 환율 급등 1도토리 조정희
1173 성장동력산업 금리: FOMC 점도표 상향에도 영향은 제한적 1도토리 조정희
1172 성장동력산업 라이브 커머스, 중국 보험업계 새로운 판매 채널로 부상 1도토리 조정희
1171 성장동력산업 기업 민첨성 확보를 위한 5가지 핵심 IT 전환 1도토리 조정희
1170 성장동력산업 ATSC 3.0 기반 감정표현 자막 수신시스템 구현 기술 1도토리 조정희